AACP
CSTL icon

Advantage Alpha Capital Partners’s Castle Biosciences CSTL Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,021
Closed -$327K – 134
2025
Q2 		$327K Sell
16,021
-3,784
-19% -$70.1K 0.09% 108
2025
Q1 		$396K Buy
+19,805
New +$490K 0.1% 101
2024
Q4 		– Sell
-10,940
Closed -$312K – 160
2024
Q3 		$312K Buy
+10,940
New +$278K 0.07% 157

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advantage Alpha Capital Partners's CSTL Position: Q3 2025 in Review

Advantage Alpha Capital Partners sold out of Castle Biosciences (CSTL) in Q3 2025, closing a stake of 16,021 shares — an estimated $327K sold.

Advantage Alpha Capital Partners first reported a position in CSTL in Q3 2024 and held it in 3 quarters. The position peaked at $396K in Q1 2025. 173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

  • Advantage Alpha Capital Partners reported no remaining Castle Biosciences position as of Q3 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 16,021 Castle Biosciences shares in Q3 2025, an estimated $327K.
  • Advantage Alpha Capital Partners first reported a position in Castle Biosciences in Q3 2024 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Castle Biosciences position peaked at $396K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2025, filed 12 Nov 2025.